ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
Dow Jones
38.675,68
1,18%
Euro vs US Dollar
1,07735
0,41%
Bitcoin
62.880,00
6,36%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Inovio Pharmaceuticals Inc New (INO)

  7. Inovio Pharmaceuticals Inc New (INO) News

INO

Inovio Pharmaceuticals (INO)

Inovio Pharmaceuticals Inc New
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:INO
DatumZeitQuelleÜberschriftSymbolFirma
01/05/202414h00PR Newswire (US)INOVIO Reports Inducement Grants Under Inducement PlanNASDAQ:INOInovio Pharmaceuticals Inc New
29/04/202414h00PR Newswire (US)INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024NASDAQ:INOInovio Pharmaceuticals Inc New
29/04/202414h00PR Newswire (US)INOVIO to Participate in Upcoming Investor Conferences in MayNASDAQ:INOInovio Pharmaceuticals Inc New
16/04/202400h39PR Newswire (US)INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsNASDAQ:INOInovio Pharmaceuticals Inc New
26/03/202423h28PR Newswire (US)INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn MedicineNASDAQ:INOInovio Pharmaceuticals Inc New
06/03/202422h05PR Newswire (US)INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsNASDAQ:INOInovio Pharmaceuticals Inc New
06/03/202413h00PR Newswire (US)Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:INOInovio Pharmaceuticals Inc New
06/03/202412h02IH Market NewsU.S. Stock Futures Gain Ahead of Economic Insights; Oil Prices ClimbNASDAQ:INOInovio Pharmaceuticals Inc New
21/02/202414h00PR Newswire (US)INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024NASDAQ:INOInovio Pharmaceuticals Inc New
07/02/202417h46PR Newswire (US)INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:INOInovio Pharmaceuticals Inc New
02/02/202414h00PR Newswire (US)INOVIO Reports Inducement Grant Under Inducement PlanNASDAQ:INOInovio Pharmaceuticals Inc New
01/02/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:INOInovio Pharmaceuticals Inc New
26/01/202422h01Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:INOInovio Pharmaceuticals Inc New
25/01/202422h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INOInovio Pharmaceuticals Inc New
23/01/202414h00PR Newswire (US)INOVIO Announces Effective Date of 1-for-12 Reverse Stock SplitNASDAQ:INOInovio Pharmaceuticals Inc New
22/01/202414h00PR Newswire (US)INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion LeaderNASDAQ:INOInovio Pharmaceuticals Inc New
12/01/202423h27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INOInovio Pharmaceuticals Inc New
04/01/202414h00PR Newswire (US)INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)NASDAQ:INOInovio Pharmaceuticals Inc New
03/01/202414h00PR Newswire (US)INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval ProgramNASDAQ:INOInovio Pharmaceuticals Inc New
28/11/202322h05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:INOInovio Pharmaceuticals Inc New
17/11/202322h00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:INOInovio Pharmaceuticals Inc New
09/11/202322h35Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:INOInovio Pharmaceuticals Inc New
09/11/202322h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INOInovio Pharmaceuticals Inc New
09/11/202322h05PR Newswire (US)INOVIO Reports Third Quarter 2023 Financial Results and Operational HighlightsNASDAQ:INOInovio Pharmaceuticals Inc New
09/11/202322h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INOInovio Pharmaceuticals Inc New
02/11/202321h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INOInovio Pharmaceuticals Inc New
01/11/202313h00PR Newswire (US)INOVIO Reports Inducement Grants Under Inducement PlanNASDAQ:INOInovio Pharmaceuticals Inc New
26/10/202314h00PR Newswire (US)INOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023NASDAQ:INOInovio Pharmaceuticals Inc New
10/10/202322h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INOInovio Pharmaceuticals Inc New
10/10/202316h51Dow Jones NewsInovio Shares Rise 8% After FDA Feedback for INO-3107NASDAQ:INOInovio Pharmaceuticals Inc New
 Showing the most relevant articles for your search:NASDAQ:INO

Kürzlich von Ihnen besucht

NYSE
MCD
McDonalds
TG
ALV
Allianz
FX
EURGBP
Euro vs Sterling
TG
432
Arbor Metals
NYSE
KO
Coca Cola
TG
MBG
MercedesBenz
COIN
SOLUSD
Solana
TG
LHA
Deutsche Lufthansa
TG
DBK
Deutsche Bank
USOTC
BNPQY
BNP Paribas (QX)
USOTC
RHHBY
Roche (QX)
NYSE
DIS
Walt Disney
CCOM
SILVER
SILVER
AMEX
XLF
Financial Select Sector
PM
XAUUSD
Gold vs US Dollar
TG
BAS
BASF
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten